High Eradication Rate of a Potassium‐Competitive Acid Blocker‐Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real‐World Study
Ji‐Yan Li, Ying‐Ying Han, Dong‐Yan Li, Jing‐Mei Liu, Zhen‐Zhen Zhou, Ya‐Ni Zhou, Lin Tuo, Xiao‐Jiao Yao, Mei Liu, Ge Wang, Pei‐Yuan Li · 2026
Read High Eradication Rate of a Potassium‐Competitive Acid Blocker‐Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real‐World Study by Ji‐Yan Li, Ying‐Ying Han, Dong‐Yan Li, Jing‐Mei Liu, Zhen‐Zhen Zhou, Ya‐Ni Zhou, Lin Tuo, Xiao‐Jiao Yao, Mei Liu, Ge Wang, Pei‐Yuan Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13179562.txt.
Description
Ji-Yan Li and co-authors test a last-resort drug mix against stubborn stomach Helicobacter infections, in this 2026 study. Many of the 368 patients at a Wuhan hospital had already failed two or more cure attempts. Resistance to standard antibiotics ran sky high among those tested. The fourteen-day regimen paired a strong new acid blocker with minocycline, furazolidone, and bismuth, three agents the bacterium still fears.
Cure rates topped ninety-two percent overall and ninety-six percent among those who completed the course. Side effects touched a quarter of patients, mostly mild dizziness and nausea. Poor pill compliance and having a peptic ulcer predicted failure. The authors offer the mix as a rescue plan where resistance testing is out of reach.
Catalog record
| CREATOR | Ji‐Yan Li, Ying‐Ying Han, Dong‐Yan Li, Jing‐Mei Liu, Zhen‐Zhen Zhou, Ya‐Ni Zhou, Lin Tuo, Xiao‐Jiao Yao, Mei Liu, Ge Wang, Pei‐Yuan Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |